Fractyl Health, Inc. (GUTS) – What Are Brokerages Thinking About This Stock?

Fractyl Health, Inc. (NASDAQ:GUTS) has earned an average recommendation of “Hold” from the five brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $50.25.

A number of brokerages recently issued reports on GUTS. Wall Street Zen cut shares of Fractyl Health from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings lowered shares of Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 3rd. Morgan Stanley decreased their target price on shares of Fractyl Health to $4.00 and set an “equal weight” rating on the stock in a research report on Monday, October 19th. Finally, Craig Hallum set a $5.00 price objective on shares of Fractyl Health in a research note on Monday, October 19th.

Fractyl Health Stock Up 3.8%

Shares of NASDAQ:GUTS opened at $0.93 on Friday. The firm has a fifty day moving average price of $4.64 and a two-hundred day moving average price of $7.47. The company has a market cap of $12.33 million, a price-to-earnings ratio of -0.09 and a beta of 2.90. The company has a debt-to-equity ratio of 1.41, a current ratio of 3.15 and a quick ratio of 3.15. Fractyl Health has a one year low of $0.82 and a one year high of $29.34.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings data on Monday, August 10th. The company reported ($1.44) EPS for the quarter, topping the consensus estimate of ($1.62) by $0.18. Analysts anticipate that Fractyl Health will post -5.88 EPS for the current fiscal year.

Institutional Investors Weigh In On Fractyl Health

Several hedge funds have recently modified their holdings of GUTS. Sanctuary Advisors LLC acquired a new stake in shares of Fractyl Health in the 2nd quarter valued at about $26,000. Accredited Investors Inc. acquired a new position in Fractyl Health in the 1st quarter valued at $46,000. FNY Investment Advisers LLC lifted its position in shares of Fractyl Health by 84.3% during the 2nd quarter. FNY Investment Advisers LLC now owns 65,420 shares of the company’s stock worth $51,000 after purchasing an additional 29,920 shares during the last quarter. PEAK6 LLC acquired a new position in shares of Fractyl Health during the 2nd quarter worth $159,000. Finally, BlackRock Inc. acquired a new stake in Fractyl Health during the 2nd quarter valued at approximately $1,431,000.

Fractyl Health Company Profile

Fractyl Health, Inc is a biotechnology company focused on developing therapies for metabolic diseases, including obesity and type 2 diabetes. The company aims to create treatments that address the underlying biology of these conditions and provide longer-lasting alternatives to frequently administered medicines.

Fractyl Health’s technology platforms include Revita, an endoscopic procedure designed to modify the lining of the duodenum and potentially improve metabolic function, and a gene therapy platform intended to enable the body to produce therapeutic levels of metabolic hormones such as glucagon-like peptide-1 (GLP-1).